ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report) shares saw unusually-high trading volume on Friday . Approximately 478,301 shares changed hands during mid-day trading, an increase of 428% from the previous session's volume of 90,568 shares.The stock last traded at $10.66 and had previously closed at $10.35.
Wall Street Analyst Weigh In
Separately, Laidlaw began coverage on shares of ABIVAX Société Anonyme in a research report on Monday, July 29th. They set a "buy" rating and a $48.00 target price on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $36.50.
Get Our Latest Stock Analysis on ABVX
ABIVAX Société Anonyme Price Performance
The firm's 50 day moving average price is $11.16 and its 200-day moving average price is $12.84.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in ABVX. BNP Paribas Financial Markets acquired a new stake in ABIVAX Société Anonyme in the first quarter worth $81,000. Capstone Investment Advisors LLC raised its stake in ABIVAX Société Anonyme by 9.0% during the 1st quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company's stock worth $900,000 after buying an additional 5,199 shares during the period. Kennedy Capital Management LLC lifted its holdings in ABIVAX Société Anonyme by 35.3% during the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company's stock worth $1,718,000 after acquiring an additional 31,331 shares in the last quarter. Finally, Janus Henderson Group PLC grew its stake in ABIVAX Société Anonyme by 18.2% in the first quarter. Janus Henderson Group PLC now owns 851,839 shares of the company's stock valued at $12,113,000 after acquiring an additional 131,414 shares during the period. 47.91% of the stock is currently owned by institutional investors.
ABIVAX Société Anonyme Company Profile
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Read More
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
